🟢 AXSM is trading 4.1% up today after TD Cowen raised its price target following Auvelity's FDA approval

AXSM is trading 4.1% up at $247.06 as the stock extends a strong multi-week rally driven by positive regulatory developments and bullish analyst sentiment.

• TD Cowen raised its price target for the stock to $300 from $275, citing continued optimism regarding the company's portfolio.
• Momentum is fueled by sustained enthusiasm surrounding the FDA approval of Auvelity for the treatment of Alzheimer’s agitation.
• The stock is significantly outperforming the broader biotech sector, highlighting strong company-specific momentum.